Breaking Immunotherapy Resistance in Melanoma: The Role of Oncolytic Virus RP1

The Significance of Advanced Melanoma

Melanoma represents about 5% of all skin cancers but is among the most aggressive subtypes. Early diagnosis greatly improves the chances of survival; however, treatment options narrow significantly as the disease progresses, often leading to poor outcomes for patients. Immunotherapies have transformed melanoma treatment over recent years, yet many patients either do not respond initially or develop resistance over time. Overcoming this resistance remains a major clinical challenge, highlighting the need for innovative therapeutic strategies such as oncolytic virus therapies.

RP1 and Nivolumab: A Powerful Immunotherapy Combination

Recent studies show promising results with a combination of RP1 (vusolimogene oderparepvec) and nivolumab in melanoma patients resistant to conventional immunotherapies.

RP1 (Vusolimogene Oderparepvec): A Targeted and Intelligent Virus Against Cancer

RP1 is a genetically modified therapeutic oncolytic virus vaccine based on Herpes Simplex Virus Type 1 (HSV-1). This specially engineered virus selectively infects and replicates within cancer cells, causing their destruction (lysis). The tumor cells' rupture releases tumor-specific antigens and immune-activating molecules, triggering a robust systemic immune response against the tumor.

Nivolumab: Breaking the Chains of Immune Suppression

Nivolumab is a modern immunotherapy targeting the PD-1 protein. Normally, PD-1 acts as a brake to prevent excessive immune reactions. However, cancer cells exploit this mechanism to evade immune detection. Nivolumab blocks PD-1, reactivating immune cells to effectively target and attack cancer cells. The combination of RP1 and nivolumab initiates a powerful dual attack, directly destroying cancer cells while simultaneously activating the immune system.

The IGNYTE Study: Effective Combination Therapy for Resistant Melanoma

The IGNYTE clinical study evaluated the efficacy and safety of the RP1 and nivolumab combination in advanced melanoma patients resistant to immunotherapy. The latest results were published in the Journal of Clinical Oncology on July 8, 2025.

Patient Profile

• A total of 140 patients participated.

• Approximately half (48.6%) had stage IVM1b/c/d melanoma.

• 65.7% had previously shown no response to anti-PD-1 therapy.

• More than half (56.4%) were PD-L1 negative, typically associated with poorer immunotherapy responses.

• 46.4% had previously received both anti-PD-1 and anti-CTLA-4 therapies.

Study Design

• RP1 was administered via direct tumor injections, with a maximum of 8 doses (additional doses permitted as needed).

• Nivolumab was administered intravenously at regular intervals for up to 2 years.

• Independent reviewers evaluated treatment responses using RECIST 1.1 criteria.

Results and Clinical Significance

• Remarkable Response Rate: An objective response was observed in 32.9% of patients, with 15% achieving complete responses.

• Durable Responses: Median duration of response was approximately 34 months, indicating lasting therapeutic benefit.

• Systemic Efficacy: Responses were seen not only in injected lesions but also in distant, uninjected tumors, including visceral metastases.

• Manageable Side Effects: Serious adverse effects were rare (12.9%), with most being mild (77.1%).

• Strong Immune Activation: Significant increases in immune cell infiltration and PD-L1 expression were observed in treated tumor sites.

Future Steps and FDA Review

In January 2025, the FDA granted the combination Priority Review status, recognizing its potential clinical value. Phase III IGNYTE-3 studies have been initiated to validate efficacy in a broader patient population.

Rise of Oncolytic Virus Therapies

Oncolytic virus therapies are not entirely new. Talimogene Laherparepvec (T-VEC), approved by the FDA in 2015, marked a major milestone in this field. RP1 represents a significantly advanced generation of this therapeutic approach, providing stronger systemic immune responses.

Conclusion: Renewed Hope for Melanoma Patients

The RP1 and nivolumab combination offers renewed hope to patients facing immunotherapy-resistant melanoma. This innovative treatment has the potential to significantly enhance survival and quality of life, heralding a new era in oncology where previously untreatable conditions may become manageable.